PRME Stock Summary and Trading Ideas (Prime Medicine | NASDAQ:PRME)

Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.

Prime Medicine trades on the NASDAQ stock market under the symbol PRME.

As of January 30, 2026, PRME stock price declined to $4.01 with 1,320,916 million shares trading.

PRME has a beta of 3.33, meaning it tends to be more sensitive to market movements. PRME has a correlation of 0.24 to the broad based SPY ETF.

PRME has a market cap of $723.85 million. This is considered a Small Cap stock.

Last quarter Prime Medicine reported $1 million in Revenue and -$.32 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.09.

In the last 3 years, PRME traded as high as $21.48 and as low as $1.11.

The top ETF exchange traded funds that PRME belongs to (by Net Assets): ARKG, XBI, VTI, IWM, VXF.

PRME has outperformed the market in the last year with a price return of +45.8% while the SPY ETF gained +15.9%. However, in the short term, PRME had mixed performance relative to the market. It has underperformed in the last 3 months, returning -11.7% vs +0.7% return in SPY. But in the last 2 weeks, PRME shares have fared better than the market returning +0.5% compared to SPY -0.2%.

PRME support price is $3.90 and resistance is $4.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRME shares will trade within this expected range on the day.